U.S. stock market update: Tourmaline Bio up 57.76%

U.S. Stock Market Midday Update Tourmaline Bio rose 57.76%. According to recent key news: On September 9, Novartis announced the acquisition of Tourmaline Bio at a price of $48 per share, valuing the company at approximately $1.4 billion. This news led to a pre-market increase of 58% in Tourmaline Bio's stock price. On September 9, the board of directors of Tourmaline Bio unanimously approved Novartis's acquisition proposal, with the transaction expected to be completed in the fourth quarter. On September 9, analysts expressed optimism about the acquisition of Tourmaline Bio, believing that the deal will complement Novartis's cardiovascular product line. The biopharmaceutical industry has shown strong performance recently, with significant capital inflows. Top Stocks by Industry Trading Volume Alnylam Pharmaceuticals rose 1.75%. Based on recent important news: On September 9, Alnylam Pharmaceuticals announced the issuance of $500 million in convertible bonds, intended for the repurchase of some 1.00% convertible bonds maturing in 2027 and for general purposes. This move aims to reduce potential dilution, pushing the stock price up by 0.4%. Data source: Company announcement. On September 8, Alnylam Pharmaceuticals had an average annual return of 15.62% over the past 10 years, outperforming the market by 3.04%. This long-term performance has boosted investor confidence, driving the stock price up. Data source: Market analysis. On September 8, analysts rated Alnylam Pharmaceuticals with 25 "strong buy" or "buy" ratings, and 7 "hold" ratings, with the target price raised from $334.50 to $448.50. Analysts' positive evaluations further supported the stock price increase. Data source: LSEG data industry trends are positive, and the macroeconomic environment is stable. AbbVie fell 0.12%, with increased trading volume. Based on recent important news: On September 9, AbbVie reached a global licensing agreement with Glenmark Pharma, paying $700 million for the development of ISB 2001. This news boosted Glenmark's stock price by 2%, but had limited impact on AbbVie's stock price. On September 8, AbbVie's new drug Skyrizi saw sales increase by 69% year-on-year, reaching $7.8 billion, despite a decline in Humira sales, the company's overall revenue grew by 8%. This performance boosted market confidence. On September 7, analysts rated AbbVie as "moderate buy," but it was not included in the top recommended stocks list, with the market holding a cautious attitude towards its future performance. The pharmaceutical industry is performing steadily overall, with a focus on patent extensions. Gilead Sciences fell 1.47%, with increased trading volume. Based on recent important news: On September 9, Xilio Therapeutics announced an exclusive licensing agreement with Gilead, receiving $17.5 million in development milestones. This news had a positive impact on Gilead's stock price but was unable to offset the overall market downtrend On September 7, analyst Daina Graybosch maintained a buy rating on Gilead with a target price of $114, emphasizing its strong position in the HIV prevention market. However, the market reacted lukewarmly to this rating, failing to boost the stock price. No other significant news. The overall market declined, affecting stock performance. Stocks ranked at the top of the industry by market capitalization Amgen fell 0.30%, with a market capitalization of $150.4 billion and increased trading volume. Based on recent key news: On September 9, Amgen and Horizon Therapeutics announced the topline results of the Phase 3 ASCEND long-term extension study of rocatinib monoclonal antibody for adult patients with moderate to severe atopic dermatitis. This news boosted market confidence in the company's R&D capabilities but failed to significantly drive up the stock price. On September 7, Amgen and Zai Lab announced the completion of the final analysis of the Phase 3 FORTITUDE-101 trial, which showed reduced survival benefits of bemarituzumab combined with chemotherapy in gastric cancer. This news raised market concerns about the drug's prospects, dragging down the stock price. On September 9, analyst Matt Phipps reiterated a buy rating on Amgen but did not provide a specific target price. The analyst noted that despite the reduced survival benefits of bemarituzumab in gastric cancer, the overall outlook for the company remains positive. The pharmaceutical industry is performing well overall, with low economic downturn risks